What Is Orforglipron (Foundayo)?
FDA-Approved — April 2026: Orforglipron received FDA approval in April 2026 and is now commercially available under the brand name Foundayo. It is the first oral small-molecule GLP-1 receptor agonist approved in the United States.
Orforglipron is a non-peptide, small-molecule oral GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide (which is a peptide requiring either injection or a complex fasting oral protocol), orforglipron is a small molecule that can be absorbed through the gut without special formulation requirements. It can be taken at any time of day, with or without food — a significant practical advantage over Rybelsus.
Why This Is Different from Rybelsus
Rybelsus requires a strict protocol: taken first thing in the morning on an empty stomach with no more than four ounces of water, followed by a 30-minute wait before eating or drinking anything else. Orforglipron's small-molecule design bypasses this entirely — absorbed through standard intestinal absorption pathways without the need for SNAC or any fasting requirement.
Phase 3 Data and Approval
Phase 3 results showed orforglipron producing approximately 14–15% body weight reduction at the highest doses in adults with obesity — efficacy comparable to Wegovy. In a head-to-head trial published in The Lancet in February 2026, orforglipron delivered superior blood sugar control and weight loss compared to oral semaglutide in adults with type 2 diabetes, which helped support its FDA approval. The drug received FDA approval in April 2026 and launched commercially as Foundayo.
Why Accessibility Matters
A meaningful proportion of people who could benefit from GLP-1 therapy decline or discontinue injectable medications due to needle aversion or logistical challenges. An effective, once-daily pill without dosing restrictions could dramatically expand access to GLP-1 therapy for this population.